We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $3.5B
1-Year Est. Return 1,165.83%
This Fund
S&P 500
This Quarter Est. Return
+54.43%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$902M
AUM Growth
+$223M
Cap. Flow
+$52.2M
Cap. Flow %
5.79%
Top 10 Hldgs %
61.32%
Holding
31
New
5
Increased
2
Reduced
1
Closed
2

Top Buys

1
GPCR icon
Structure Therapeutics
GPCR
+$34.8M
2
TRML
Tourmaline Bio
TRML
+$20.2M
3
ABVX
Abivax
ABVX
+$11.2M
4
VTGN icon
VistaGen Therapeutics
VTGN
+$10.1M
5
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$6.7M

Top Sells

1
TSHA icon
Taysha Gene Therapies
TSHA
+$16.3M
2
IMVT icon
Immunovant
IMVT
+$12.9M
3
MRUS
Merus
MRUS
+$7.07M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GPCR icon
1
Structure Therapeutics
GPCR
$3.29B
$86M 9.54%
2,109,584
+606,837
+40% +$34.8M
INBX
2
DELISTED
Inhibrx, Inc. Common Stock
INBX
$66.5M 7.38%
1,750,387
– –
ICVX
3
DELISTED
Icosavax, Inc. Common Stock
ICVX
$58.4M 6.47%
3,703,704
– –
ANTX icon
4
AN2 Therapeutics
ANTX
$169M
$54.9M 6.09%
2,678,209
– –
RYZB
5
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$54.1M 6%
869,908
– –
JBIO
6
Jade Biosciences
JBIO
$1.27B
$49.8M 5.52%
62,894
– –
GERN icon
7
Geron
GERN
$911M
$49.3M 5.47%
23,375,839
– –
SVRA icon
8
Savara
SVRA
$1.15B
$47M 5.21%
10,000,000
– –
GRCL
9
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$45.3M 5.03%
4,514,786
+1,475,897
+49% +$6.7M
MDGL icon
10
Madrigal Pharmaceuticals
MDGL
$12.4B
$41.6M 4.62%
179,917
– –
KALV
11
DELISTED
KalVista Pharmaceuticals
KALV
$41.6M 4.61%
3,395,495
– –
SLN
12
Silence Therapeutics
SLN
$493M
$36.6M 4.05%
2,104,875
– –
CMPS
13
Compass Pathways
CMPS
$1.7B
$33.8M 3.74%
3,858,000
– –
COGT icon
14
Cogent Biosciences
COGT
$6.48B
$33.1M 3.67%
5,631,042
– –
TYRA icon
15
Tyra Biosciences
TYRA
$1.87B
$27.5M 3.06%
1,989,103
– –
TRML
16
DELISTED
Tourmaline Bio
TRML
$26.4M 2.93%
+1,007,902
New +$20.2M
TARS icon
17
Tarsus Pharmaceuticals
TARS
$2.55B
$23.1M 2.57%
1,142,857
– –
DYN icon
18
Dyne Therapeutics
DYN
$3.73B
$21.9M 2.43%
1,650,150
– –
KURA icon
19
Kura Oncology
KURA
$964M
$20.5M 2.27%
1,423,642
– –
CNTA
20
DELISTED
Centessa Pharmaceuticals
CNTA
$16.2M 1.8%
2,040,816
– –
VTGN icon
21
VistaGen Therapeutics
VTGN
$9.81M
$13.8M 1.53%
+2,676,580
New +$10.1M
ABVX
22
Abivax
ABVX
$11.7B
$11.8M 1.31%
+1,100,000
New +$11.2M
CABA icon
23
Cabaletta Bio
CABA
$427M
$11.1M 1.23%
486,795
– –
TRDA icon
24
Entrada Therapeutics
TRDA
$264M
$8.83M 0.98%
584,955
– –
NRIX icon
25
Nurix Therapeutics
NRIX
$2.4B
$7.41M 0.82%
+717,654
New +$4.92M
1
2

Similar funds

DILIC
Dai-ichi Life Insurance Company Tokyo, Japan $3.49B AUM 27.28% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.51B AUM 39.24% 1-Year Est. Return
KCM
Kedalion Capital Management London, United Kingdom $3.48B AUM 17.74% 1-Year Est. Return
ACM
Aquatic Capital Management Chicago, Illinois $3.48B AUM 24.9% 1-Year Est. Return
BCP
BDT Capital Partners Chicago, Illinois $3.51B AUM 31.02% 1-Year Est. Return
AL
Aspiriant LLC Los Angeles, California $3.51B AUM 13.98% 1-Year Est. Return
ACA
Anchor Capital Advisors Boston, Massachusetts $3.51B AUM 16.99% 1-Year Est. Return
MSC
MUFG Securities (Canada) New York $3.48B AUM 45.13% 1-Year Est. Return